Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment.

about

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment.

Item

http://www.wikidata.org/entity/Q38989447

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Tyrosine kinase inhibitors in ...... nd non-adherence to treatment.

@en

type

Item

label

Tyrosine kinase inhibitors in ...... nd non-adherence to treatment.

@en

prefLabel

Tyrosine kinase inhibitors in ...... nd non-adherence to treatment.

@en

P1476

Tyrosine kinase inhibitors in ...... nd non-adherence to treatment.

@en

P2093

Karina S Aguiar

http://www.w3.org/2001/XMLSchema#string

Tatiane Farias

http://www.w3.org/2001/XMLSchema#string

Valquíria D Antunes

http://www.w3.org/2001/XMLSchema#string

Vaneuza M Funke

http://www.w3.org/2001/XMLSchema#string

Vânia M Andrzejevski

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.

Medical care costs associated with progression of diabetic nephropathy.

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Assessment of pharmacist-led patient counseling in randomized controlled trials: a systematic review.

The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

P304

559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18549/PHARMPRACT.2015.02.559

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucas Miyake Okumura

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26131044

http://www.w3.org/2001/XMLSchema#string

P932

4482844

http://www.w3.org/2001/XMLSchema#string